CNBCLean R·
Replimune to resubmit twice-rejected drug for approval after FDA shakeup
Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.
Read at CNBC →
Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.
<iframe src="https://statesidedaily.com/embed/cluster/01d3a75bce1a9118ebafce3aa8ab9406d15bf488" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Replimune to resubmit twice-rejected drug for approval after FDA shakeup"></iframe>